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Background: Estimating the prognosis in malignant pleural mesothelioma (MPM) remains challenging. Thus, the prognostic
relevance of Ki67 was studied in MPM.
Methods: Ki67 index was determined in a test cohort of 187 cases from three centres. The percentage of Ki67-positive tumour
cells was correlated with clinical variables and overall survival (OS). The prognostic power of Ki67 index was compared with other
prognostic factors and re-evaluated in an independent cohort (n¼ 98).
Results: Patients with Ki67 higher than median (415%) had significantly (Po0.001) shorter median OS (7.5 months) than those with
low Ki67 (19.1 months). After multivariate survival analyses, Ki67 proved to be—beside histology and treatment—an independent
prognostic marker in MPM (hazard ratio (HR): 2.1, Po0.001). Interestingly, Ki67 was prognostic exclusively in epithelioid (Po0.001)
but not in non-epithelioid subtype. Furthermore, Ki67 index was significantly lower in post-chemotherapy samples when
compared with chemo-naive cases. The prognostic power was comparable to other recently published prognostic factors (CRP,
fibrinogen, neutrophil-to-leukocyte ratio (NLR) and nuclear grading score) and was recapitulated in the validation cohort
(P¼ 0.048).
Conclusion: This multicentre study demonstrates that Ki67 is an independent and reproducible prognostic factor in epithelioid
but not in non-epithelioid MPM and suggests that induction chemotherapy decreases the proliferative capacity of MPM.
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Malignant pleural mesothelioma (MPM) is a devastating and often
asbestos exposure-associated malignancy with still rising incidence
worldwide. Aggressive biological behaviour, therapy resistance and
the lack of approved screening methods for early detection result in
a median overall survival (OS) of 9 to 17 months only (Tsao et al,
2009). The diagnosis of MPM can be rather challenging and several
diagnostic immunohistochemical markers might be necessary to
confirm the diagnosis of MPM including WT-1, cytokeratin CK5/6,
calretinin, EMA, podoplanin and mesothelin (Scherpereel et al,
2010). As differential diagnostic markers, the detection of CEA,
TTF-1, CD15, MOC-31, B72.3 or Ber-Ep4 argues against the
diagnosis of MPM (Scherpereel et al, 2010; Husain et al, 2013).
However, with regard to prognostic biomarkers, no established
immunohistochemical marker exists at the moment to routinely
assess prognosis in MPM. Currently, histological subtype is the
only established pathological tumour characteristic to routinely
estimate the prognosis of MPM patients (Sandeck et al, 2010;
Scherpereel et al, 2010).
Ki67 is a nuclear protein that is detectable in every phase of the
cell cycle of proliferating cells but is absent in G0 cells (Gerdes et al,
1984; Yerushalmi et al, 2010). It is therefore widely utilised as a
proliferation marker in tumour specimens (Yerushalmi et al, 2010).
Ki67 index has been reported to be prognostic in a number of
thoracic malignancies including small cell and non-small cell lung
cancer (Dingemans et al, 1999; Scagliotti et al, 1993). The mitotic
index—reflected by Ki67—is also a diagnostic tool for the
identification of pre-neoplastic bronchial lesions and used for
tumour classification in neuroendocrine tumours of the lung
(Meert et al, 2004; Skov et al, 2010). Ki67 staining on cytological
preparations from pleural effusions has been studied as a potential
diagnostic marker to discriminate between reactive mesothelial
cells and mesothelioma (Hasteh et al, 2010). Ki67 was found to be
prognostic in peritoneal mesothelioma (Baratti et al, 2013; Pillai
et al, 2013). In MPM patients with short-term and long-term OS,
the mitotic index (as determined by the MIB-1 antibody) was
reported to differ significantly (Comin et al, 2000; Bongiovanni
et al, 2001; Leonardo et al, 2001). Furthermore, Ki67 has been
studied in two retrospective patient cohorts previously (Kahlos
et al, 2000; Beer, 2001). In a recent study, a nuclear grading score
was introduced and was found to be prognostic in epithelioid
MPM. This score includes mitotic index that was alone a
significant predictor of survival (cutoff: 10% positive tumour cells)
in this tissue microarray analysis (Kadota et al, 2012). In addition,
Bitanihirwe et al (2014) found a prognostic value of Ki67 in
treatment-naı¨ve MPM patients as well as in patients after induction
therapy using tissue microarrays . However, Ki67 is still not an
established tool to estimate prognosis in MPM and validation
studies showing an independent and reproducible prognostic
power are needed before Ki67 can be introduced as a reliable
biomarker in MPM. In the present study, we investigated whether
Ki67 index measured on whole slides after immunohistochemistry
staining is an independent and, furthermore, reproducible
prognostic factor in a large international cohort consisting of 187
patients from three different centres and, moreover, in an
additional independent validation cohort of 98 patients from yet
another centre, adding up to a total of 285 MPM cases.
PATIENTS AND METHODS
Patients. The test cohort consisted of 187 patients from three
centres. In Croatia (CRO), 91 patients were included by the
University of Zagreb, School of Medicine, Department for
Respiratory Diseases Jordanovac. The Hungarian cohort (HUN)
consisted of 42 cases from the National Koranyi Institute of TB and
Pulmonology, Budapest. About 54 cases were included in Austria
(AUT) at the Division of Thoracic Surgery, Medical University of
Vienna. In addition, 98 patients from the Department for
Pulmonology, University Clinic Golnik in Slovenia (SLO) were
analysed as an independent validation cohort. All 285 MPM
patients were referred to one of the four institutions between 1994
and 2012. Inclusion criteria were a reliable clinical follow-up and
available representative paraffin-embedded tumour specimen. In
all analysed patients, MPM diagnosis was histologically proven
during clinical routine work-up. The IMIG staging system (Rusch,
1995) was used for clinical and pathological tumour staging. All
tumour samples were collected either during surgery (n¼ 71) or as
part of diagnostic procedures. Clinical data and tumour blocks
were retrospectively collected for all cases according to the
corresponding local ethic committees.
The CRO cohort (91 patients) involved 85 epithelioid and 6
non-epithelioid MPMs. The majority of patients was treated by
chemo and/or radiotherapy (n¼ 46), followed by best supportive
care in 29 patients and macroscopic radical surgery alone (n¼ 6)
or within a multimodality therapy protocol (n¼ 6). In 4 patients,
information about the applied treatment was unavailable in the
medical records. In the HUN cohort (42 cases), only three patients
received surgery within a multimodality treatment protocol and
two additional patients were treated by surgery alone. The
epithelioid morphology was the most frequent (n¼ 33) subtype
followed by sarcomatoid (n¼ 5) and biphasic (n¼ 4) MPM.
In the AUT cohort, all 54 patients underwent macroscopic
complete resection. Extrapleural pneumonectomy was performed
in the majority of cases (n¼ 52), as previously described (Aigner
et al, 2008). One patient underwent pleurectomy/decortication as
defined by Sugarbaker and Wolf (2010), and one additional patient
received macroscopic radical local tumour resection followed by
adjuvant radiotherapy. All tumour samples were collected during
surgery. About 29 patients (53.7%) received induction chemother-
apy before surgery and 23 patients (42.6%) were treated with
adjuvant therapy after resection (radiation: n¼ 10, chemotherapy:
n¼ 8, chemo-radiation: n¼ 5), resulting in 36 patients receiving a
combination of surgery with adjuvant and/or neoadjuvant
treatment (multimodality treatment group). About 18 patients
were treated with surgery alone (surgery-alone group). The most
frequent histological subtype was the epithelioid (n¼ 38) followed
by the biphasic (n¼ 16). No patient in the AUT cohort had
sarcomatoid MPM, due to the fact that this histology is a
controversial candidate for macroscopic radical tumour resection
(Stahel et al, 2010). The majority of all AUT patients (57.4%) had
pathologically classified late stage disease according to the post-
operative report (stage III and IV; n¼ 31).
About 98 SLO patients were analysed as an independent
validation cohort to re-evaluate Ki67 as a reproducible prognostic
marker. For the SLO cohort, we used the median Ki67 expression
as a cutoff as later described because the tumour samples were
scored by an independent pathologist different than the one in the
test cohort. Also in this cohort, the epithelioid subtype was the
most frequent one (n¼ 77) followed by the biphasic (n¼ 15) and
the sarcomatoid (n¼ 6).
Tumour samples. All 285 histological specimens were fixed in
formalin and embedded in paraffin (FFPE). One 4-mm section
from a representative, tumour-rich FFPE block was stained by
haematoxylin/eosin to confirm and locate malignant areas and
consecutive sections were used for Ki67 immunohistochemistry.
Sections were deparaffinised with xylene and rehydrated with
decreasing alcohol concentrations. After heat-induced epitope
retrieval in citrate buffer (10mmol l 1, pH 6.0), slides were
incubated at room temperature with the Ki67 antibody (mono-
clonal mouse antibody, Dako Cytomation (Dako, Glostrup,
Denmark), clone MIB-1, dilution 1 : 100, incubation time:
30min). Antibody binding was detected by means of the
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UltraVision LP detection system (Lab Vision Corporation,
Fremont, CA, USA) according to the manufacturer’s recommen-
dations. Colour development was achieved by 3-3-diaminobenzi-
dine. Finally, all analysed slides were counterstained with Mayer’s
haematoxylin.
Ki67 scoring. Evaluation of the staining was independently
performed by one pathologist (US) in the test cohort and by
another independent pathologist (IS) in the validation cohort, both
had no information about the clinical history of cases and only
received anonymized slides for evaluation and scoring. Both
pathologists scored the HUN cohort to test the inter-observer
reproducibility. Counting was limited to proven tumour tissue and
only nuclear staining was scored as positive. First, the whole tissue
section was reviewed at low magnification to identify the regions
with the highest viable tumour cell content. The hot-spot approach
was used to measure areas with the highest proliferative activity.
Whenever possible, up to 10 high-power fields were analysed and
at least 500 tumour cells were counted to calculate the mean
percentage of Ki67-positive tumour cells per analysed sample.
Nuclear grading score was determined by a board certified
pathologist (IS) as previously described by Kadota et al (2012).
First, the area with the highest degree of atypia was investigated.
The nuclear size and nuclear irregularity was graded as 1 for mild
atypia (uniform nuclei), 2 for moderate atypia (intermediate size
nuclei and some irregularity in shape), 3 for severe atypia
(prominent enlarged nuclei). Next, mitotic count was estimated
per 10 high-power fields and the patients were allocated to group 1
for low mitotic count, 2 for intermediate mitotic count and 3 for
high mitotic count. Finally, nuclear grading score was calculated as
the sum of nuclear atypia and mitotic count (ranging from 2 to 6).
The nuclear grading score was dichotomized into the low (2, 3 and 4)
and high (5 and 6) groups for survival analyses. The nuclear grading
was performed for 59 epithelioid MPM patients where all other
prognostic parameters were available.
Statistical analyses. Metric data is always given as median and
corresponding range, or, in case of survival, as median and
corresponding 95% confidence interval (CI) if not otherwise
indicated. Overall survival was defined as time between MPM
diagnosis and death or, in censored patients, diagnosis and last
follow-up date. Survival was analysed by the Kaplan–Meier method
and log rank test or by the Cox-regression model to calculate
hazard ratios (HRs) and corresponding CIs. In the test cohort,
patients were divided into high and low Ki67 index groups by the
median (15%). Accordingly, 92 patients were allocated to the high
(415%) and 95 patients to the low Ki67 index group (p15%).
Since the validation cohort was scored by a different independent
pathologist, we again used median Ki67 expression of the
validation group (22%) for dichotomizing into the low (n¼ 52)
and high Ki67 (n¼ 46) expressing groups. One-way ANOVA and
unpaired t-tests were used to compare the mean of parametric
distributed metric data between than two groups and more two
groups, respectively. Mann–Whitney U-test was used for non-
parametric distributed metric data. w2-test was performed for
analysing the association between categorical factors. The correla-
tion of metric data was analysed by Pearson’s correlation
coefficient. Receiver operating characteristic (ROC) analysis was
performed in the epithelioid subtype from the full cohort with a
follow-up of 412 months (n¼ 221) to investigate the sensitivity
and specificity of Ki67 in predicting short-term survival using the
median OS of 12 months as cutoff. Furthermore, we validated three
other recently published blood prognostic MPM biomarkers in
patients where this information was available. About 118 patients
were analysed for the neutrophil-to-lymphocyte ratio (NLR) (Kao
et al, 2010; Kao et al, 2011), 97 patients for C-reactive protein
(CRP) (Ghanim et al, 2012) and finally 127 patients for fibrinogen
levels (Ghanim et al, 2014) using cutoffs from the aforementioned
studies. In addition, in 65 patients, all three aforementioned
biomarkers were available and could therefore be directly
compared with each other and to Ki67 in ROC analyses. All
statistical analyses were calculated with the PASW Statistics 18.0
package (Predictive Analytics Software, SPSS Inc., Chicago, IL,
USA). P-values are given as two-sided and were considered
statistically significant below 0.05.
RESULTS
Histological subtype and treatment modality influence OS in
MPM. The test cohort consisted of 40 female (21.4%) and 147
male (78.6%) histologically verified MPM patients (n¼ 187, mean
age: 60.2±10.6 years; range: 28–82 years). About 156 patients
suffered from epithelioid MPM (83.4%) compared with 31 non-
epithelioid MPM patients (16.6%) including 22 biphasic (11.8%)
and 9 sarcomatoid (4.8%) cases. In the test cohort, 123 patients
were diagnosed at the late stage of the disease (78.3%). With regard
to therapy, 26 patients were treated by surgery alone (13.9%), 45
patients received multimodality therapy regimens including
macroscopic radical tumour surgery (24.1%), 53 patients were
treated by chemo and/or radiotherapy (28.3%) and further 33
patients had best supportive care only (17.6%). In 30 patients
(16% of the test cohort), treatment information was not available.
In 33 patients, induction chemotherapy was applied prior to surgery.
Median OS in the test cohort was 12.0 months (CI 9.3–14.7). In
univariate survival analyses, histology (Figure 1A and Table 1) and
treatment (Figure 1C, Table 1) were found to have prognostic
value. Meanwhile, gender, age and disease stage (Figure 1B) had no
significant impact on patient’s OS in univariate survival analyses of
the test cohort (Table 1).
Ki67 index is not associated with histology and stage but
significantly decreased in post-chemotherapy cases. Ki67 index
was determined on tumour sections following immunohisto-
chemical staining (Figure 2A). In the HUN cohort, both
pathologists scored the staining to test the inter-observer
reproducibility. The scoring of this cohort, by the two pathologists
(US and IS), showed a strong and significant correlation (Pearson’s
correlation coefficient: 0.668, Po0.001, n¼ 41).
The median percentage of Ki67-positive tumour cells was
15.0% (range: 0–60%) for the entire test cohort (n¼ 187). Patient
characteristics according to low and high Ki67 index dichotomized
by the median are shown in Table 2. There was no significant
difference in the distribution of Ki67 index with regard to age, sex,
histology or stage. The Ki67 labelling showed no association with
histology (mean±s.d.: epithelioid 16.3±12.9 vs non-epithelioid
18.2±14.6, P¼ 0.465 or epithelioid 16.3±12.9 vs biphasic
18.3±15.3 vs sarcomatoid 18.2±13.6, P¼ 0.766, Figure 2B). In
line with this finding, the distribution of the histological subtypes
within the high and low Ki67 index groups did not differ
significantly (P¼ 0.554, Table 2; also compare representative
pictures of the histological subtypes with high and low Ki67
labelling in Figure 2A). Furthermore, no association of Ki67 index
and disease stage was found in the test cohort, and there was only a
non-significant modest tendency towards higher Ki67 index in late
stage of the disease (17.6±13.2 vs early stage 13.9±13.6,
P¼ 0.144, Figure 2C). However, patients in the multimodality
treatment group more frequently had low Ki67 index when
compared with the other treatment groups. Accordingly, the Ki67
index differed significantly between patients treated by induction
therapy (n¼ 33, mean Ki67 index: 10.5±8.5) and the rest of the
test cohort who had not received chemotherapy before sample
collection (n¼ 124, mean Ki67 index: 18.3±13.9, Po0.001,
Figure 2D).
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Ki67 is an independent prognostic marker only in epithelioid
MPM. MPM patients with high Ki67 index had significantly worse
outcome when compared with the low Ki67 index group (HR 2.3,
CI 1.7–3.2, Po0.001) in univariate survival analyses of the test
cohort. Accordingly, median OS in the low Ki67 group (19.1
(CI 11.7–26.5) months) was significantly (Po0.001) higher than in
the patients with high Ki67 index (7.5 (CI 5.2–9.8) months,
Figure 3A). Furthermore, we performed multivariate analyses to
clarify whether Ki67 is also an independent prognostic marker in
MPM. We therefore utilised a multimodality Cox-regression model
adjusted for age (dichotomized by the median age of 61.5 years),
gender, stage (early vs late stage), histology (epithelioid vs non-
epithelioid MPM), treatment (surgery alone vs best supportive care
vs chemo and or radiotherapy vs multimodality therapy including
macroscopic complete surgery) and Ki67 index (dichotomized
by 15%) including 149 patients with all aforementioned parameters
available in the medical records (missing cases: n¼ 38).
After multivariate survival analyses, Ki67 index proved to be an
independent prognostic marker in MPM (HR: 2.1, CI: 1.4–3.1,
Po0.001) beside histology (P¼ 0.013) and treatment modality
(P¼ 0.001), whereas age, gender and stage had no independent
prognostic impact on OS of the test cohort as shown in Table 3.
After subgroup analyses, Ki67 only showed a prognostic power in
the epithelioid subtype (Ki67 low: 22.9 (CI 17.8–27.9) months vs
Ki67 high: 7.9 (CI 5.3–10.4) months, Po0.001 Figure 3B) whereas
it had no prognostic impact in the non-epithelioid subtype (Ki67
low: 4.9 (CI 0–10.9) vs Ki67 high: 6.3 (CI 2.4–10.2) months,
P¼ 0.630) as shown in Figure 3C. In all other subgroup analyses
(for age, gender, stage and treatment), Ki67 proved to be—
according to the multivariate analysis—a prognostic marker in all
except the surgery-alone subgroup. Accordingly, an additional
analysis was performed to investigate whether surgical treatment
influences the prognostic power of Ki67. Interestingly, Ki67 proved
to be a prognosticator both for surgically treated patients
(multimodality group and surgery-alone group high vs low Ki67
OS: 7.9 vs 18.5 months; P¼ 0.001) as well as for patients without
surgical treatment regimens (chemo and/or radiotherapy alone and
best supportive care group high vs low Ki67 OS: 7.6 vs 22.9
months; Po0.001).
Ki67 index is a reproducible prognostic marker. To confirm the
prognostic value of Ki67 in MPM, we have analysed the
independent SLO cohort (n¼ 98; 21 female, 77 male; mean age:
66.9±9.0 years; range: 42–84 years). Median Ki67 count in the
SLO validation cohort was 22% (range: 2–70.) Accordingly, we
dichotomized this cohort also by its median Ki67 index, resulting
in 46 patients allocated to the high (422%) and 52 patients
allocated to the low Ki67 group. Again, patients with high Ki67
index had significantly worse outcome when compared with those
with low Ki67 index. OS was 18.2 months in the low Ki67 group
(CI 12.4–24.1 months) vs 9.1 months (CI 5.4–12.9 months, log
rank test: P¼ 0.048; Figure 3D) in the high Ki67 expression group.
Ki67 is an accurate marker predicting short-term survival in
epithelioid MPM. To test the sensitivity and specificity for
detecting early death (death before median OS of 12 months was
reached), ROC curve analysis was performed. We therefore
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Figure 1. Overall survival prognosticators in MPM. (A) The three
histological subtypes are characterised by different outcomes
(epithelioid 12.8 (CI 10.5–15.0) months vs biphasic 7.2 (CI 0–20.7) vs
sarcomatoid 5.6 (CI 2.5–8.7) months, P¼0.005). (B) Disease stage had
no significant impact on OS (late stage 10.8 (CI 7.3–14.3) months vs
early stage 15.4 (CI 13.1–17.8) months, P¼ 0.305). (C) Treatment has
robust prognostic impact on OS (multimodality therapy 18.5 (CI 8.2–
28.8) months vs chemo and/or radiotherapy 13.9 (CI 9.6–18.3) months
vs best supportive care (BSC) 7.6 (CI 4.4–10.8) months vs surgery alone
5.3 (CI 0.8–9.7) months, Po0.001).
Table 1. Univariate survival analyses in the test cohort
(n¼187)
Characteristics OS (CI) Pa HR (CI)
Age, years
p61.5 12.2 (10.0–14.5) 84 0.97 (0.72–1.31)
461.5 10.3 (5.2–15.4) — —
Sex
Female 11.3 (9.6–13.0) 0.17 0.76 (0.51–1.13)
Male 12.1 (8.6–15.6) — —
Histology
Epithelioid 12.8 (10.5–15.0) o0.01 1
Biphasic 7.2 (0–20.7) — —
Sarcomatoid 5.6 (2.5–8.7) — —
Stageb
Early stage 15.4 (13.1–17.8) 0.31 1.24 (0.82–1.87)
Late stage 10.8 (7.3–14.3) — —
Treatmentb
Surgery alone 5.3 (0.8–9.7) o0.01 1.30 (0.76–2.21)
Best supportive care 7.6 (4.4–10.8) — 1
Chemo and/or radiotherapy 13.9 (9.6–18.3) — 0.61 (0.39–0.95)
Multimodality treatment
including radical surgery
18.5 (8.2–28.8) — 0.46 (0.28–0.74)
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; OS¼overall survival.
aTwo-sided log rank test.
bMissing cases: n¼ 30 (16.0%).
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analysed all epithelioid MPM patients with clinical follow-up for at
least 12 months (n¼ 221). In this analysis, Ki67 showed an area
under the curve of 0.68 (Figure 4A). The sensitivity and specificity
at 15% (the cutoff value used in the test cohort) were 0.69 and 0.57,
respectively.
Comparison of Ki67 index and prognostic blood parameters. A
number of inflammation- related blood parameters have recently
been reported to reflect the prognosis of MPM. Therefore the
correlation of Ki67 index to NLR, fibrinogen and CRP has been
studied. Ki67 only showed a weak albeit significant correlation to
fibrinogen (n¼ 127, Pearson’s correlation coefficient 0.324,
Po0.001) but not to the other proinflammatory markers (CRP:
n¼ 97 and NLR: n¼ 118). Of note, a significant correlation
(n¼ 92, Pearson’s correlation coefficient 0.530, Po0.001) was
found between the two acute phase proteins, namely fibrinogen
and CRP.
Nevertheless, patients with high Ki67 index had more frequently
elevated CRP (P¼ 0.001, n¼ 97), fibrinogen 4627mg dl 1
(Po0.001, n¼ 127) and a (non-significant) tendency to have a
NLR 45 (P¼ 0.160, n¼ 118). Next, we performed subgroup
analyses to clarify if Ki67 index adds prognostic information on
top of the prognostic power provided by the proinflammatory
parameters. Interestingly, Ki67 was found to be prognostic in
patients with elevated CRP (P¼ 0.022). Due to the low number
(n¼ 3) of patients with normal CRP but high Ki67 index, the
normal CRP subgroup could not be analysed. With regard to
fibrinogen, Ki67 was prognostic in both the high (P¼ 0.028) and
low (P¼ 0.005) fibrinogen groups. Furthermore, Ki67 was also
found to be prognostic in both the high (P¼ 0.001) and low
(Po0.001) NLR groups, indicating that indeed Ki67 adds
prognostic information to the recently published proinflammatory
parameters.
To compare the prognostic power of these three aforementioned
MPM biomarkers with Ki67, an additional ROC analysis was
performed. Ki67, NLR, fibrinogen and CRP showed areas under
the curve of 0.70, 0.72, 0.62 and 0.71, respectively, indicating that
Ki67 index carries comparable prognostic power to these recently
published prognostic proinflammatory markers (Figure 4B).
Comparison of the nuclear grading score with Ki67 index and
other prognostic parameters. Finally, we wanted to compare the
prognostic value of Ki67 index and the nuclear grading score as
previously described by Kadota et al (2012). To compare all
prognostic parameters, we determined the nuclear grading score
for the patients included in the ROC analysis. The nuclear grading
score was established for 59 patients. With regard to nuclear atypia,
3 patients were allocated to the mild and 33 patients to the
moderate nuclear atypia group. Accordingly, we compared these 36
patients to 23 patients with tumours characterised by severe atypia.
Based on mitotic count analysis, 20 patients were allocated to the
low, 20 patients to the intermediate and 19 patients to the high
mitosis group. In this case, we combined low and intermediate
groups and contrasted them to the high mitotic count patients.
Altogether, 35 and 24 patients had low (2–4) and high (5 and 6)
nuclear grading score, respectively.
Patients with mild or moderate nuclear atypia had significant
longer median OS (14.1, CI 8.2–20.1 months) than patients with
severe nuclear atypia (9.1, CI 2.8–15.4 months, P¼ 0.022).
Furthermore, Ki67 expression was significantly higher in the
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Figure 2. Ki67 index in MPM tissue samples. (A) Ki67 nuclear staining in all three major histological subtypes of MPM. Scale bar is 100mm.
(B) There was no significant difference between the three histological subtypes with regard to Ki67 index (mean±s.d.: epithelioid 16.3±12.9 vs
biphasic 18.3±15.3 vs sarcomatoid 18.2±13.6, P¼0.766). (C) Modest increase of Ki67 index in late stage of disease (mean±s.d.: 17.6±13.2) vs
early stage (13.9±13.6, P¼ 0.144). (D) Patients after induction chemotherapy had significantly lower amount of Ki67-positive tumour cells when
compared with the treatment naı¨ve patients in the test cohort (mean±s.d.: induction chemotherapy 10.5±8.5 vs chemo-naı¨ve 18.3±13.9,
asterisk denotes significance of Po0.001).
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severe nuclear atypia group when compared with the mild
and moderate atypia groups (mean±s.d.: 25.43±16.22 vs
15.58±11.06, P¼ 0.015).
Patients with high mitotic count had a—not significant—
tendency for shorter median OS (11.3, CI 2.3–20.3 months) when
compared with those with intermediate and low mitotic counts
(13.6, CI 11.9–15.2 months, P¼ 0.063). As expected, the Ki67
index was significantly higher in the high mitotic count group
when compared with the low and intermediate count group
(mean±s.d.: 27.3±13.9 vs 15.7±12.6, P¼ 0.002).
Table 2. Patient characteristics and distribution according to Ki67 expression in the test cohort (n¼187)
Low Ki67 High Ki67 All patients
Characteristics Numbers % Numbers % Numbers % P-value
Age, Years
p61.5 50 53.2 44 46.8 94 50.3 NS*
461.5 45 48.4 48 51.6 93 49.7 —
Sex
Female 25 62.5 15 37.5 40 21.4 NS*
Male 70 47.6 77 52.4 147 78.6 —
Histology
Epithelioid 81 51.9 75 48.1 156 83.4 NS*
Non- Epithelioid 14 45.2 17 54.8 31 16.6 —
Stage#
early stage 22 64.7 12 35.3 34 21.7 NS*
late stage 60 48.8 63 51.2 123 78.3 —
Treatment#
Surgery alone 12 46.2 14 53.8 26 16.6 0.02*
Best supportive care 13 39.4 20 60.6 33 21 —
Chemo and/or Radiotherapy 24 45.3 29 54.7 53 33.8 —
Multimodal treatment 32 71.1 13 28.9 45 28.7 —
Surgery#
Surgery 44 62 27 38 71 45.2 0.02*
No Surgery 37 43 49 57 86 54.8 —
Induction Therapy#
Induction 25 75.8 8 24.2 33 21 0.01*
Chemo-naı¨ve at sampling
time
56 45.2 68 54.8 124 79 —
Abbreviations: NS¼not significant. ‘*’¼ two-sided w2-test; ‘#’¼missing cases: n¼ 30 (16.0%).
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Figure 3. Prognostic power of Ki67 index in MPM. (A) Kaplan–Meier survival analysis of the test cohort (n¼ 187). There was a significant difference
in the OS between patients with high (n¼ 92) vs low (n¼ 95) Ki67 index (HR 2.3, CI 1.7–3.2, Po0.001). Median OS was higher in low Ki67 index
(o15%) group (19.1 (CI 11.7–26.5) months) than in patients with high Ki67 index (7.5 (CI 5.2–9.8) months, Po0.001)). (B) Kaplan–Meier survival
curve shows that Ki67 is prognostic in epithelioid MPM. (C) In contrast, there is no impact of Ki67 index on OS in patients with non-epithelioid
MPM (n¼ 31). (D). Kaplan–Meier survival analysis in the validation cohort (n¼98). Ki67 had a significant impact on OS (P¼ 0.048) when using
median Ki67 expression of the validation cohort as cutoff (22%).
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With regard to nuclear grading score, the low score group had
significantly longer OS (14.9, CI 8.5–21.3 months) when compared
with the high score group (9.1, CI 2.4–15.9, P¼ 0.019). According
to the previous analyses, Ki67 index was significantly higher in the
high nuclear grading group when compared with the low nuclear
grading group (mean±s.d.: 27.6±14.1 vs 13.8±11.1, Po0.001).
The inflammatory related marker CRP tended to be higher in
the high nuclear grading group (5.78±3.98mgdl 1) when compared
with the low nuclear grading group (4.14±4.26mg dl 1,
P¼ 0.140). A similar tendency was observed with regard to mean
fibrinogen levels in the nuclear grading groups high vs
low (675.71±225.13 vs 572.49±188.90mg dl 1, respectively,
P¼ 0.062). Also for the NLR, the nuclear grading tended to be
more frequently high in the high fibrinogen group when compared
with the low fibrinogen group (Pearsons w2-test, P¼ 0.166).
Finally, we performed a univariate analysis for predicting an OS
of o12 months for all biomarkers studied (Table 4). All factors,
but the mitotic count, were significant prognosticators.
DISCUSSION
In the present study, we performed a comprehensive analysis of the
prognostic power of Ki67 index in MPM. Besides known
prognostic factors such as histological subtype and treatment
modality, Ki67 index was found to be an OS prognosticator in a
test cohort of 187 patients. The large international patient cohort
provided us the opportunity to show that the prognostic value of
the proliferation index is indeed independent of age, sex, stage,
histology and treatment in the test cohort patients with full clinical
record (n¼ 149). In addition, we were able to reproduce and verify
the prognostic power of this routine proliferation marker in an
independent cohort of 98 patients from a different centre.
Furthermore, we were able to compare the prognostic power of
Ki67 index with other recently published prognostic markers
including CRP (Ghanim et al, 2012), fibrinogen (Ghanim et al,
2014), NLR (Kao et al, 2010; Kao et al, 2011) and nuclear grading
score (Kadota et al, 2012).
In MPM, Ki67 expression detected in serous effusions was
described to correlate with OS, but did not reach statistical
significance in a series of 20 patients (Schonherr et al, 2004).
Furthermore, Ki67 index was found to differ significantly between
long- and short-term MPM survivors in three small series in the
past (Comin et al, 2000; Bongiovanni et al, 2001; Leonardo et al,
2001). In a more recent study, a nuclear grading system—that
includes mitotic index—was found to be prognostic in the
epithelioid subtype of MPM (Kadota et al, 2012) in tissue
microarray analyses when using 10% as cutoff. In addition,
Bitanihirwe et al (2014), found a prognostic value of Ki67 in
treatment-naı¨ve MPM patients as well as in patients after induction
therapy in tissue microarray analyses. In the aforementioned study,
a cutoff of 20% Ki67-positive tumour cells was used in chemo-
naı¨ve patients, whereas 11.25% was used as cutoff in patients after
induction therapy (Bitanihirwe et al, 2014). Importantly, our study
on whole FFPE blocks—a clinically more relevant material as
compared with TMA—used similar cutoff values for the respective
subgroups. Of note, when using the cutoff value for induction
therapy patients from the study of Bitanihirwe et al (2014),
(11.25%), Ki67 index was prognostic in the induction therapy
subcohort from our study (OS: 30.9 vs 15.4 months, P¼ 0.020,
n¼ 33).
Table 3. Cox-regression model adjusted for patient
characteristics of all test cohort patients with available
complete data for model adjustment (n¼149)
Characteristics
Adjusted HR for
death 95% CI
Adjusted
P-value
Age, years
p61.5 0.98 0.69–1.40 0.92
461.5 1 — —
Sex
Female 0.94 0.53–1.67 0.84
Male 1 — —
Histology
Epithelioid 1 — 0.01
Non-epithelioid 1.90 1.14–3.15 —
Stage
Early stage 0.64 0.36–1.12 0.12
Late stage 1 — —
Treatment
Surgery alone 1.44 0.75–2.80 0.28
Best supportive care 1 — —
Chemo and/or
Radiotherapy
0.58 0.36–0.93 0.02
Multimodal treatment 0.52 0.30–0.91 0.02
Ki67 Expression
Low Ki67 1 — o0.01
High Ki67 2.11 1.44–3.10
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio.
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Figure 4. Sensitivity and specificity analyses of Ki67 by ROC analysis. (A) in all epithelioid MPM patients with follow-up of at least 12.0 months
(n¼221) showed an area under the curve of 0.68. The sensitivity and specificity at 15% (cutoff used in the test cohort) were 0.69 and 0.57,
respectively. (B) Ki67 index, neutrophil-to-lymphocyte ratio (NLR), fibrinogen and C-reactive protein (CRP) showed areas under the curve of 0.70,
0.72, 0.62 and 0.71, respectively (n¼ 65).
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Importantly, we hereby describe for the first time that Ki67 is
only prognostic in the epithelioid but not in the non-epithelioid
histological subtype of MPM. Similar to Hirano et al (2002), we
could not show a significant difference in the proportion of Ki67-
positive tumour cells between the epithelioid and non-epithelioid
histological subtypes (Figures 2A and B). Previously, Kadota et al
(2012) only analysed epithelioid MPM patients and the very recent
study of Bitanihirwe et al (2014) did not report subgroup analyses
with regard to Ki67 and histology. However, when using the cutoff
from the study by Kadota et al (2012) (10%), Ki67 again was only
prognostic in the epithelioid (Po0.001) but not in the non-
epithelioid subtype (P¼ 0.715).
Furthermore, in our study, Ki67 index was also not associated
with other clinical characteristics, such as gender, age or tumour
stage but showed a—not significant—tendency to be more
frequently increased in late stage of disease as also shown in
Figure 2C. Of note, high Ki67 index was also associated with the
proinflammatory phenotype—reflected by elevation of the recently
published MPM prognosticators CRP (Ghanim et al, 2012),
fibrinogen (Ghanim et al, 2014) and the NLR (Kao et al, 2010;
Kao et al, 2011)—indicating that an elevated systemic immune
response of the patient is associated with a more proliferative
tumour phenotype. In line with these findings, the nuclear grading
score tended to be associated with a proinflammatory status.
Nevertheless, our study demonstrated that ki67 index was
prognostic in both subgroups of patients dichotomized by the
inflammation-related parameters. These observations argues for a
more aggressive biological MPM subtype associated with high Ki67
expression and might, in addition to tumour stage and proin-
flammatory phenotype, help pathologists to further classify MPM
according to their biological behaviour. However, in subgroup
analyses, Ki67 was prognostic in both early as well as late stage of
disease excluding the fact that Ki67 expression simply reflects
clinically undetected late stage of disease.
Importantly, we could detect significant differences of Ki67
expression between the treatment groups. This observation can be
explained by the high number of patients after induction therapy in
the multimodality therapy group (33 out of 45 patients in the
multimodality group received induction chemotherapy before
surgery/sampling of the tumour). Figure 2D shows the lower
amount of Ki67-positive tumour cells in patients after induction
chemotherapy, reflecting the lower number of mitotic tumour cells
after chemotherapy. This is in line with the recently published
observations of Bitanihirwe et al (2014) and, therefore, suggests
that Ki67 index might also be a clinically useful marker to estimate
biological response achieved by (induction-) chemotherapy. Again,
the treatment subgroup analyses demonstrated that Ki67 was
prognostic in all treatment cohorts except the surgery-alone group.
However, the surgery-alone group was the smallest and resulted in
the worst outcome. This may impair the proper statistical analysis
of this subgroup in terms of prognostic power. Furthermore, we
showed that Ki67 was prognostic in both surgically treated patients
(multimodality therapy group and surgery-alone group) as well as
in non-surgically treated patients (chemo and/or radiotherapy
alone and best supportive care patients). Multivariate survival
analyses proved that the prognostic value of Ki67 is independent of
age, sex, stage, histology and treatment modality. Besides Ki67
expression, univariate survival analyses revealed—in line with
previous studies (Aigner et al, 2008; van Zandwijk et al, 2013)—
histology and treatment as prognostic factors. Also, the recently
published proinflammatory biomarkers CRP (Ghanim et al, 2012),
fibrinogen (Ghanim et al, 2014) and NLR (Kao et al, 2010; Kao
et al, 2011) were found to have prognostic value in this large MPM
cohort. Furthermore, we could also validate the prognostic power
of the nuclear grading score (Kadota et al, 2012). After multivariate
analyses, Ki67 index, histological subtype and treatment remained
as significant prognosticators. Patients who received surgery as
single treatment modality survived significantly shorter than those
treated within multimodality treatment protocols as previously
published by our group (Aigner et al, 2008). Our multicentre study
with a large patient population strongly supports the importance of
interdisciplinary treatment in MPM.
We also demonstrated that Ki67 index has a prognostic power
similar to other recently described inflammation-related blood
parameters (Kao et al, 2010; Kao et al, 2011; Ghanim et al, 2012;
Ghanim et al, 2014). In the ROC analysis, Ki67 index was found to
be an accurate prognosticator with an area under the curve of 0.70.
Importantly, there was a strong correlation between fibrinogen and
CRP, suggesting that these two acute phase proteins reflect the
same biological characteristics of MPM patients. At the same time,
NLR and Ki67 index did not correlate, indicating that these two
parameters might deliver additional biological information in
MPM patients. Of note, in our study cohort, CRP, fibrinogen and
NLR were also found to be of prognostic value when all three
markers were analysed as metric characteristics. Our finding thus
supports the prognostic power of NLR that is recently heavily
debated (Meniawy et al, 2013; Kao et al, 2014; Meniawy et al,
2014).
In summary, the current study demonstrates that Ki67 index is
an accurate prognostic marker in epithelioid MPM indicating the
proportion of proliferating tumour cells and reflecting a more
aggressive biological behaviour. It can significantly contribute to
the estimation of the course of the disease as other studies—similar
to our findings—have indicated that the current staging system
does not have sufficient prognostic power (Edwards et al, 2000;
Tanrikulu et al, 2010). Accordingly, the histological classification
and staging of MPM needs further improvement to better reflect
biological behaviour and consequently estimate more precisely the
clinical outcome of MPM patients.
In the present study, Ki67 index demonstrated significant
prognostic power in two independent study cohorts. The introduction
Table 4. Comparison of prognostic biomarkers in univariate
survival analyses
Characteristics
Number of
patients Pa HR (CI)
C-reactive protein
p1 mg dl 1 97 o0.01 2.55 (1.39–4.65)
41 mg dl1 — — —
Fibrinogen
p627 mg dl 1 127 o0.01 1.85 (1.26–2.72)
4627 mg dl1 — — —
NLR
o5 118 0.01 1.76 (1.14–2.71)
X5 — — —
Nuclear atypia
Mild and moderate 59 0.03 1.97 (1.09–3.57)
Severe — — —
Mitotic count
Low and
intermediate
59 0.07 0.58 (0.33–1.04)
High — — —
Nuclear grading score
Low (2–4) 59 0.02 1.95 (1.11–3.45)
High (5 and 6) — — —
Ki67 index
p15 59 o0.01 2.58 (1.42–4.69)
415 — — —
Abbreviations: CI¼ confidence interval; HR¼hazard ratio; NLR-neutrophil-to-lymphocyte
ratio.
aCox regression.
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of Ki67 index as a prognostic tool into the daily pathological
routine work-up of MPM is feasible as Ki67 is already in use as a
prognostic marker in other cancer types and, furthermore,
immunohistochemical protocols for detection of Ki67 expression
are relatively inexpensive, reliable and used worldwide. We,
therefore, conclude that Ki67 index is useful to estimate the
prognosis of epithelioid MPM and might also be a novel tool to
evaluate the biological treatment response after induction
chemotherapy.
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